Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • proton therapy
Proton Beam vs IMRT for Olfactory Neuroblastoma: Too Little Data for a Definitive Answer — What the New Propensity-Matched Cohort Tells Us
Posted innews Oncology Otorhinolaryngology

Proton Beam vs IMRT for Olfactory Neuroblastoma: Too Little Data for a Definitive Answer — What the New Propensity-Matched Cohort Tells Us

Posted by MedXY By MedXY 11/19/2025
A multi-institutional propensity-matched cohort found no definitive differences in oncologic outcomes or grade ≥2 radiotherapy toxicities between adjuvant proton beam radiotherapy and IMRT for olfactory neuroblastoma, but estimates were imprecise and underpowered.
Read More
  • Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial
  • Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer
  • Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC
  • National Expertise and Molecular Profiling Extend Survival in Cancer of Unknown Primary: Insights from the French CUP MTB
  • Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in